Harnessing the power of cutting-edge AI technologies, the Larkai ecosystem revolutionizes the diagnosis of complex cardiopulmonary anomalies. With real-time quantitative analysis, it achieves early disease detection in under 30 seconds, slashing the gold-standard timeline by an unprecedented 40%. Founded in 2020, the Medtech startup Larkai bridges the critical gap between diagnosis and treatment, making the process more accessible, affordable, and precise, ensuring patients receive prompt, life-saving care.
In an exclusive conversation with The Interview World, Abhilash Chakraverty, Co-founder and Director of Larkai Healthcare Private Limited, reveals how their groundbreaking Medtech products are transforming healthcare diagnosis. He offers deep insights into diagnosing critical diseases and emphasizes the vital role of policymakers in accelerating the development of indigenous Medtech innovations. Here are the pivotal takeaways from his interview.
Q: Can you provide an overview of the main products and services that Larkai offers?
A: Larkai Healthcare Private Limited is a trailblazing Medtech SaaS AI platform dedicated to revolutionizing healthcare. We deliver affordable, accessible care to everyone at a fraction of the cost. Anchored in the Gurgaon NASSCOM Centre of Excellence, we’ve been spearheading this change for over three and a half years.
Q: What distinct features and innovations set your platform apart from other healthcare providers in the market?
A: In India, a staggering 84% of medical devices in hospitals and diagnostic centers come from abroad. We’ve flipped the script with our groundbreaking IoT AI-enabled device, crafted right here in India and priced at just a quarter of what imported devices cost. This revolutionary Medtech solution makes it not only feasible but cost-effective for hospitals to equip emergency rooms, operating theaters, and ICUs with multiple devices. The result? A dramatic surge in both turnover and productivity for healthcare facilities.
Q: Do you believe Larkai has the potential to revolutionize the entire healthcare sector? If so, in what ways?
A: Our technology isn’t just advanced; it’s a game changer. We deliver top-of-the-line solutions at a mere fraction—one-quarter, to be precise—of the current industry benchmarks. This potent mix of cutting-edge innovation and unbeatable pricing isn’t just compelling; it’s irresistible. By slashing costs while setting new standards in technology, we offer unparalleled value. We’re not just keeping pace; we’re miles ahead. This strategic advantage doesn’t just make us a choice; it makes us the choice. Our value proposition redefines the market, putting us in a league of our own and making competitors irrelevant.
Q: Which specific diseases will these medical devices have the most significant impact on?
A: In India, the dominant culprits behind disease and death are cardiovascular diseases and cancer, with infectious diseases trailing behind. Our mission zeroes in on these pressing issues. Cardiovascular diseases and cancer together claim around 3 million lives annually—lives that could be saved with the right intervention. Enter our groundbreaking tool: it provides an unparalleled early warning system that predicts heart attacks up to two years in advance. No other solution offers this level of foresight. By catching potential issues early, we can prevent countless deaths and transform health outcomes. This proactive approach isn’t just innovative; it’s a game-changer in saving lives and reshaping public health.
Q: How can policymakers support and accelerate the development and adoption of similar technology-driven products in India?
A: We’ve invested significant effort into making startups successful, but the bulk of MedTech innovation still happens beyond India’s borders. Startup India, NASSCOM, and Hartron are all stepping up to support startup growth, and we’re eager for this support to extend to critical areas like computing power.
Right now, we’re heavily reliant on Taiwan for silicon inductors and NVIDIA for GPUs. What we need is a robust ecosystem where Indian companies can manage the entire value chain. The government should incentivize domestic production of these high-tech components, which are currently imported. This shift would be a game-changer.
